European regulators are still probing the safety of Novartis AG's multiple sclerosis pill Gilenya, one of the Swiss firm's top new drug hopes, delaying an expected update on the medicine until April.
The European Medicines Agency (EMA) initially aimed to give an update on the medicine by March 16 but a spokeswoman said on Friday that the review had not yet been finalised. As a result, an announcement is now due on April 19 or 20.
The delay leaves a question mark over the product, which has seen its prospects clouded by concern about serious heart problems.
But there was also good news for Gilenya as Britain's healthcare cost-effectiveness watchdog NICE, in an about-turn, decided it was ready to recommend its use on the state health service.
Gilenya, the first multiple sclerosis (MS) pill of its kind, is seen by analysts as a potential blockbuster with annual sales of $2 billion by 2015, according to consensus forecasts collected by Thomson Reuters Pharma.
However, that is down on the $2.2 billion seen at the end of 2011 as doctors have grown more cautious about the drug following reports of heart problems in some patients and the death of one person in the United States within 24 hours of starting treatment.
Those cases prompted the EMA to start its review in January, when it also advised doctors to continuously monitor patients for six hours after giving them a first dose. The U.S. Food and Drug Administration (FDA) is also looking into the drug.
Novartis said in a statement it was working with the EU regulator to finalise the label for Gilenya and was also liaising with the FDA on its review.
Gilenya represents a significant change in MS treatment, since existing medicines like beta interferons and Elan and Biogen Idec's Tysabri must be injected.
Rival oral MS treatments in development include BG-12 from Biogen, teriflunomide from Sanofi and laquinimod from Teva.
Britain's National Institute for Health and Clinical Excellence (NICE), whose opinions are also watched closely in other countries, initially said it was unclear if Gilenya was any better than existing treatments.
It changed its mind after Novartis presented data showing benefit in a subgroup of adults with highly active disease, whose relapses had increased or stayed the same compared with the previous year despite them taking beta interferons.
Carole Longson, director of NICE's health technology evaluation centre, said it was now clear Gilenya was a cost-effective option for these patients, provided Novartis supplied the drug at the discounted price it previously suggested.
A NICE spokeswoman said the size of the discount remained confidential. The list price for 28 capsules is 1,470 pounds ($2,300) or just over 19,000 pounds per person for a year.
Novartis and Britain's MS Society welcomed the final NICE decision, which is expected to be officially published next month. ($1 = 0.6376 British pounds)
Activists decry decision by Cambodia’s Ministry of Labour, one warning could lead to civil unrest
The move was cheered by the Zambia Congress of Trade Unions and Federation of Free Trade Unions
With overnight temperatures already nudging below freezing in Ukraine, European Commission President Jose Manuel Barroso hailed an accord clinched in Brussels
Xinhua said China has sent 20 teams to Thailand, the Philippines, Malaysia, Cambodia and other neighbouring countries, arresting 75 suspects.
Supporters say law will return country to energy self-sufficiency; critics say it is too lenient on companies.
The toll is expected to be introduced in 2016. Motorists have to pay it by registering their license plates via the internet. Foreigners can also pay the levy at gas stations
Moscow's Arbitration Court ruled in favour of prosecutors who said Bashneft was unlawfully sold to local authorities in the early 2000s before being sold in 2009 to oil-to-telecoms conglomerate Sistema
Waste oil from Chinese dinner tables to power airplanes by converting into aviation biofuel
The World Bank announced Singapore had been ranked the best country to do business in for a ninth consecutive year
LPG "certainly provides lower carbon dioxide per unit of energy than diesel and petrol when used in vehicles" expert claims
52 countries and regions including Germany, UK and South Africa agree to exchange financial information
OPEC members have previously said they wanted oil at around $100 a barrel
World stocks rose on Wednesday, lifted by strong corporate earnings and investor optimism that the U.S. Federal Reserve won't raise interest rates for some time, even as it is expected to officially wind down its bond-buying stimulus programme
London-based solar plant developer aims to bring solar power generated in Tunisia to Europe as electricity in 2018.
All 48 of the country's nuclear reactors were gradually taken offline following Fukushima, the world's worst nuclear disaster since Chernobyl in 1986.
British PM said the bill made it harder to make the case to keep Britain in the European Union before a membership referendum he has promised in 2017 if he is re-elected next year.